ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1179

Bicarbonate Target in Treating Renal Acidosis: Is Higher Better?

Session Information

Category: Fluid, Electrolyte, and Acid-Base Disorders

  • 902 Fluid, Electrolyte, and Acid-Base Disorders: Clinical


  • Dwal, Ashraf, Ochsner Medical Center - New Orleans, New Orleans, Louisiana, United States

Metabolic acidosis is commonly seen in patients with CKD from a decrease in ammonium excretion which gets buffered by the extracellular bicarbonate, hence, low plasma carbon dioxide is a surrogate of acidosis. treatment of acidosis (usually sodium bicarbonate to decrease the progression of, maintain bone health, nutrition status, In clinical practice, we aim for plasma bicarbonate of ≥ 22 mmol/L, the upper limit target is unclear.


This was a single-center retrospective chart review of CKD patients with acidosis from 2010-2017. Inclusion criteria were adult patients receiving NaHco3 for CKD-associated acidosis with baseline estimated glomerular filtration rate (eGFR) ≥25 and < 60 ml/min/1.73 m2 when starting NaHco3. Patients with glomerulonephritis, kidney transplant, acute kidney injury (not back to at least 75% of (eGFR) baseline) were excluded. Four groups were identified for comparison based on mean serum Co2 (in mmol/L), from outpatient measures during 3 years follow-up, group A (< 22), group B (22 - < 24), group C (24 - <25), and Group D (≥ 25). Albumin, urine protein-creatinine ratio (UPCR), PTH, and eGFR were compared, p-values are calculated by a one-way ANOVA model.


There were 383 patients with CKD-associated acidosis receiving NaHco3, 93 patients qualified for the study. Group A (n=21), group B (n=41), group C (n=13), and Group D (n=18). Racial demographics: 35=black (38%),57=white (61%), 1=Other. Females 49 (53%). Median age 69 years. Follow-up 3 years.
At baseline mean eGFR, UPCR, and albumin, and diuretics use and osteoporosis diagnosis in the four groups were similar (p = 0.46, 0.32, 0.15, 0.09, 0.36 respectively). Mean hemoglobin A1C in each group did not exceed 8.2. At 3 years of follow-up, changes in eGFR, UPCR, and osteoporosis status between the four groups were similar (p ≥ 0.14, ≥ 0.27, ≥ 0.19 respectively).Change of albumin was significantly worse in group A comparing to groups B, and C (p = 0.007, 0.049 respectively), and average PTH was significantly worse in group A comparing to group C (p = 0.045).


In our cohort, all groups of treated CKD-associated acidosis (B, C, and D) showed no statistical difference in CKD progression, the severity of parathyroidism, developing osteoporosis, or nutrition status assessed after 3years follow-up. Hence, higher Co2 targets don’t carry worse outcomes.